Related Experiment Video

Updated: May 8, 2026

A Rat Model of Compound Acne
03:10

A Rat Model of Compound Acne

Published on: November 1, 2024

A small peptide with therapeutic potential for inflammatory acne vulgaris

Zhiye Zhang1, Lixian Mu, Jing Tang

  • 1Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, China ; University of Chinese Academy of Sciences, Beijing, China.

Plos One
|September 10, 2013
PubMed

Insights

A novel peptide, LZ1, demonstrates potent antimicrobial activity against acne-causing bacteria, particularly Propionibacterium acnes. This peptide also reduces inflammation and shows high stability, suggesting it could be a promising acne treatment.

Area of Science:

  • Biochemistry
  • Dermatology
  • Microbiology

Background:

  • Acne vulgaris is a common skin condition caused by bacteria like Propionibacterium acnes.
  • Current treatments face challenges with efficacy and resistance.

Purpose of the Study:

  • To evaluate the antimicrobial and anti-inflammatory properties of a designed peptide, LZ1.
  • To assess LZ1's potential as a therapeutic agent for acne vulgaris.

Main Methods:

  • Antimicrobial activity testing against acne-related bacteria.
  • In vivo efficacy assessment using a mouse skin colonization model.
  • Analysis of inflammatory factor inhibition and cytotoxicity.

Main Results:

  • LZ1 exhibited strong antimicrobial activity against Propionibacterium acnes, Staphylococcus epidermidis, and Staphylococcus aureus.
  • Minimal inhibitory concentration (MIC) against P. acnes was 0.6 µg/ml, significantly lower than clindamycin.
  • LZ1 reduced P. acnes colonization, ear swelling, and inflammatory cell infiltration in mice.
  • The peptide inhibited key inflammatory factors (TNF-α, IL-1β) and showed low cytotoxicity and high plasma stability.

Conclusions:

  • LZ1 possesses significant bactericidal and anti-inflammatory effects relevant to acne treatment.
  • Its simple structure, stability, and safety profile make LZ1 a potential candidate for novel acne therapies.

More Related Videos

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...